Literature DB >> 16087724

Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species.

Spyridon Arampatzis1, Bert Kadereit, Daniela Schuster, Zoltan Balazs, Roberto A S Schweizer, Felix J Frey, Thierry Langer, Alex Odermatt.   

Abstract

11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1), catalyzing the intracellular activation of cortisone to cortisol, is currently considered a promising target to treat patients with metabolic syndrome; hence, there is considerable interest in the development of selective inhibitors. For preclinical tests of such inhibitors, the characteristics of 11beta-HSD1 from the commonly used species have to be known. Therefore, we determined differences in substrate affinity and inhibitor effects for 11beta-HSD1 from six species. The differences in catalytic activities with cortisone and 11-dehydrocorticosterone were rather modest. Human, hamster and guinea-pig 11beta-HSD1 displayed the highest catalytic efficiency in the oxoreduction of cortisone, while mouse and rat showed intermediate and dog the lowest activity. Murine 11beta-HSD1 most efficiently reduced 11-dehydrocorticosterone, while the enzyme from dog showed lower activity than those from the other species. 7-ketocholesterol (7KC) was stereospecifically converted to 7beta-hydroxycholesterol by recombinant 11beta-HSD1 from all species analyzed except hamster, which showed a slight preference for the formation of 7alpha-hydroxycholesterol. Importantly, guinea-pig and canine 11beta-HSD1 displayed very low 7-oxoreductase activities. Furthermore, we demonstrate significant species-specific variability in the potency of various 11beta-HSD1 inhibitors, including endogenous compounds, natural chemicals and pharmaceutical compounds. The results suggest significant differences in the three-dimensional organization of the hydrophobic substrate-binding pocket of 11beta-HSD1, and they emphasize that species-specific variability must be considered in the interpretation of results obtained from different animal experiments. The assessment of such differences, by cell-based test systems, may help to choose the appropriate animal for safety and efficacy studies of novel potential drug candidates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16087724     DOI: 10.1677/jme.1.01736

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  19 in total

1.  Mutations of key hydrophobic surface residues of 11 beta-hydroxysteroid dehydrogenase type 1 increase solubility and monodispersity in a bacterial expression system.

Authors:  Alexander J Lawson; Elizabeth A Walker; Scott A White; Timothy R Dafforn; Paul M Stewart; Jonathan P Ride
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

2.  Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1.

Authors:  Arne Meyer; Anna Vuorinen; Agnieszka E Zielinska; Petra Strajhar; Gareth G Lavery; Daniela Schuster; Alex Odermatt
Journal:  Drug Metab Dispos       Date:  2013-06-26       Impact factor: 3.922

Review 3.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 4.  Virtual screening applications in short-chain dehydrogenase/reductase research.

Authors:  Katharina R Beck; Teresa Kaserer; Daniela Schuster; Alex Odermatt
Journal:  J Steroid Biochem Mol Biol       Date:  2017-03-09       Impact factor: 4.292

5.  Inhibition of 11β-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole.

Authors:  Katharina R Beck; Murielle Bächler; Anna Vuorinen; Sandra Wagner; Muhammad Akram; Ulrich Griesser; Veronika Temml; Petra Klusonova; Hideaki Yamaguchi; Daniela Schuster; Alex Odermatt
Journal:  Biochem Pharmacol       Date:  2017-01-25       Impact factor: 5.858

6.  Species used for drug testing reveal different inhibition susceptibility for 17beta-hydroxysteroid dehydrogenase type 1.

Authors:  Gabriele Möller; Bettina Husen; Dorota Kowalik; Leena Hirvelä; Dariusz Plewczynski; Leszek Rychlewski; Josef Messinger; Hubert Thole; Jerzy Adamski
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

7.  Influence of human serum albumin on the bile acid-mediated inhibition of liver microsomal type 1 11β-hydroxysteroid dehydrogenase.

Authors:  Yorio Maeda; Mayumi Funagayama; Akio Shinohara; Chihiro Koshimoto; Hidemi Furusawa; Hiroshi Nakahara; Yukiko Yamaguchi; Tomokazu Saitoh; Takashi Yamamoto; Kansei Komaki
Journal:  J Physiol Biochem       Date:  2014-08-10       Impact factor: 4.158

8.  Impaired oxidoreduction by 11β-hydroxysteroid dehydrogenase 1 results in the accumulation of 7-oxolithocholic acid.

Authors:  Carlos A Penno; Stuart A Morgan; Anna Vuorinen; Daniela Schuster; Gareth G Lavery; Alex Odermatt
Journal:  J Lipid Res       Date:  2013-08-09       Impact factor: 5.922

9.  A novel NADP(+)-dependent dehydrogenase activity for 7alpha/beta- and 11beta-hydroxysteroids in human liver nuclei: A third 11beta-hydroxysteroid dehydrogenase.

Authors:  B Robinzon; R A Prough
Journal:  Arch Biochem Biophys       Date:  2009-05-03       Impact factor: 4.013

Review 10.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.

Authors:  Karen Chapman; Megan Holmes; Jonathan Seckl
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.